News
SAGE
6.99
+0.14%
0.01
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 12h ago
Weekly Report: what happened at SAGE last week (0923-0927)?
Weekly Report · 4d ago
SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324
NASDAQ · 09/27 14:27
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sage Therapeutics, Inc.(SAGE) Shareholders
Barchart · 09/27 04:45
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate
Benzinga · 09/26 14:38
Sage To Resume Full Ownership Of SAGE-324 Program As Biogen Terminates Collaboration Deal
NASDAQ · 09/26 12:10
BUZZ-Sage Therapeutics falls after Biogen terminates tremor drug partnership
Reuters · 09/26 11:45
SAGE Therapeutics’ SAGE-324 Collaboration with Biogen Ends
TipRanks · 09/26 11:28
Sage Therapeutics, Biogen End Licensing Agreement for Tremor Drug
Dow Jones · 09/26 11:28
Biogen to end Sage deal for neuro candidate
Seeking Alpha · 09/26 11:20
Sage Therapeutics announces discontinuation of SAGE-324 pact with Biogen
TipRanks · 09/26 11:12
Sage Therapeutics Announced That Biogen Has Terminated Its Rights Under The Collaboration And License Agreement With Sage Specific To The SAGE-324 Program
Benzinga · 09/26 11:03
SAGE THERAPEUTICS INC - TO EVALUATE OTHER POTENTIAL INDICATIONS FOR SAGE-324
Reuters · 09/26 11:00
SAGE THERAPEUTICS INC - BIOGEN TERMINATES RIGHTS UNDER SAGE-324 PROGRAM
Reuters · 09/26 11:00
SAGE THERAPEUTICS INC <SAGE.O>: JP MORGAN CUTS TARGET PRICE TO 1,240P FROM 1,250P
Reuters · 09/26 03:14
Weekly Report: what happened at SAGE last week (0916-0920)?
Weekly Report · 09/23 10:23
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sage Therapeutics, Inc. (SAGE)
Barchart · 09/18 13:40
Sage Therapeutics files for $250M of common stock
Seeking Alpha · 09/17 19:36
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sage Therapeutics, Inc. (SAGE)
Barchart · 09/17 17:37
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAGE
Barchart · 09/17 16:57
More
Webull provides a variety of real-time SAGE stock news. You can receive the latest news about Sage Therapeutic through multiple platforms. This information may help you make smarter investment decisions.
About SAGE
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABA receptors, targeting both synaptic and extra synaptic GABA receptors. Its product ZULRESSO (brexanolone) CIV injection is for the treatment of PPD in individuals 15 years old and older. It is also developing a portfolio of other novel compounds that target GABA receptors, including SAGE-324, which is a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing. Its second area of focus for development is novel compounds that target the NMDA receptor.